Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
Pharmacology, Toxicology and Pharmaceutical Science
35
8%
Biochemistry, Genetics and Molecular Biology
25
6%
Agricultural and Biological Sciences
22
5%
Immunology and Microbiology
19
4%
Other
54
12%
Unknown
120
27%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 41. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 September 2024.
All research outputs
#1,209,904
of 32,106,825 outputs
Outputs from The Lancet
#8,815
of 50,090 outputs
Outputs of similar age
#8,496
of 228,896 outputs
Outputs of similar age from The Lancet
#106
of 588 outputs
Altmetric has tracked 32,106,825 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 50,090 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 63.7. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 228,896 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 588 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.
